Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AST’s blossoming stent trial

This article was originally published in The Gray Sheet

Executive Summary

Advanced Stent Technologies expects to receive FDA approval to begin enrollment "in the next several months" of up to 100 patients at four to six U.S. sites to study its Petal coronary bifurcation bare-metal stent. The firm received conditional approval for use of Petal and its delivery system in 30 nonrandomized patients in its U.S. BOSS study on Sept. 3. FDA had cleared an investigational device exemption for Petal in December 2001 for a 30-patient feasibility study (1"The Gray Sheet" Sept. 3, 2004, p. 27). AST gained a CE mark for a rapid-exchange version of its SLK-View DSX stent for treating bifurcated lesions in February 2003...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts